151 related articles for article (PubMed ID: 31589184)
1. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Wiegand J; Buggisch P; Mauss S; Boeker KHW; Klinker H; Müller T; Günther R; Serfert Y; Manns MP; Zeuzem S; Berg T; Hinrichsen H; C-Registry GH
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1424-1431. PubMed ID: 31589184
[TBL] [Abstract][Full Text] [Related]
2. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.
Ridruejo E; Garcia-Agudo R; Mendizabal M; Aoufi-Rabih S; Dixit V; Silva M; Fabrizi F
Nefrologia (Engl Ed); 2020; 40(1):46-52. PubMed ID: 31229261
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
6. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
Butt AA; Ren Y; Puenpatom A; Arduino JM; Kumar R; Abou-Samra AB
Aliment Pharmacol Ther; 2018 Jul; 48(1):35-43. PubMed ID: 29797514
[TBL] [Abstract][Full Text] [Related]
8. Ledipasvir/sofosbuvir; ombitasvir/paritaprevir/ritonavir/dasabuvir sodium monohydrate; and peramivir.
Hussar DA; Kavelak HL
J Am Pharm Assoc (2003); 2015; 55(2):216, 219-20, 222. PubMed ID: 25749267
[No Abstract] [Full Text] [Related]
9. Viral hepatitis: new hepatitis C therapies-a medical pick and mix.
Ray K
Nat Rev Gastroenterol Hepatol; 2014 Jun; 11(6):329. PubMed ID: 24776807
[No Abstract] [Full Text] [Related]
10. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Evon DM; Sarkar S; Amador J; Lok AS; Sterling RK; Stewart PW; Reeve BB; Serper M; Reau N; Rajender Reddy K; Di Bisceglie AM; Nelson DR; Golin CE; Lim JK; Fried MW
J Hepatol; 2019 Sep; 71(3):486-497. PubMed ID: 31096006
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study.
Mazzaro C; Dal Maso L; Quartuccio L; Ghersetti M; Lenzi M; Mauro E; Bond M; Casarin P; Gattei V; Crosato IM; De Vita S; Pozzato G
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):107-114. PubMed ID: 29465371
[TBL] [Abstract][Full Text] [Related]
13. Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
Ravinetto R; De Weggheleire A; Dorlo TP; Francque S; Sokkab A; Pouget C; Meessen B; Tabernero P; Newton PN; Lynen L
Trop Med Int Health; 2016 Dec; 21(12):1490-1495. PubMed ID: 27671365
[No Abstract] [Full Text] [Related]
14. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Özer Etik D; Suna N; Öcal S; Selçuk H; Dağlı Ü; Çolak T; Hilmioğlu F; Boyacıoğlu AS; Haberal M
Exp Clin Transplant; 2019 Feb; 17(1):52-58. PubMed ID: 30719954
[TBL] [Abstract][Full Text] [Related]
16. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
[TBL] [Abstract][Full Text] [Related]
17. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
[TBL] [Abstract][Full Text] [Related]
19. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Steiner S; Bucsics T; Schwabl P; Mandorfer M; Scheiner B; Aichelburg MC; Grabmeier-Pfistershammer K; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
Wien Klin Wochenschr; 2017 Aug; 129(15-16):517-526. PubMed ID: 28130599
[TBL] [Abstract][Full Text] [Related]
20. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Cheng EY; Saab S; Holt CD; Busuttil RW
Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]